华森制药：获得药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug registration certificate of Crizotinib capsules, indicating a significant advancement in its product portfolio [1] Group 1: Product Approval - The product Crizotinib capsules are primarily used for the treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients [1] - Crizotinib is also indicated for ROS1-positive advanced non-small cell lung cancer (NSCLC) patients [1]